MMSI Stock Balance Sheets

Merit Medical Systems Quarterly Balance Sheets Chart

Quarterly

Annual

Goodwill

Cash and Cash Eq

Inventory

Merit Medical Systems Quarterly Balance Sheets Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2011-12-31	2011-09-30	2011-03-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-09-30	2005-06-30	2005-03-31	2004-09-30	2004-06-30	2004-03-31


current assets:
cash and cash equivalents	341,819,000	395,529,000	376,715,000	523,128,000	636,658,000	581,921,000	587,036,000	58,673,000	72,084,000	57,945,000	58,408,000	51,481,000	63,003,000	53,875,000	67,750,000	68,904,000	69,672,000	58,519,000	56,916,000	44,551,000	49,702,000	50,080,000	44,320,000	37,315,000	35,182,000	49,522,000																									5,819,000	3,465,000	5,298,000	4,254,000	5,992,000		5,763,000	4,873,000	16,430,000	31,081,000	26,756,000	23,757,000		12,199,000	9,281,000	9,645,000		7,005,000	7,644,000	9,014,000	11,976,000	18,835,000	28,617,000	34,434,000	35,865,142
trade receivables — net of allowance for credit losses — 2025 — 10,108 and 2024 — 9,729	204,162,000
other receivables	14,292,000	17,116,000	16,588,000	15,325,000	10,612,000	10,980,000	10,517,000	13,576,000	12,634,000	14,559,000	12,992,000	10,827,000	10,627,000	11,748,000	17,763,000	10,659,000	8,376,000	8,719,000	7,774,000	8,073,000	8,214,000	9,246,000	10,016,000	11,751,000	11,520,000	10,694,000	-2,754,000	255,000	966,000	898,000	-3,557,000	-503,000	-168,000	374,000	1,146,000	3,385,000	2,126,000	1,367,000	387,000	-735,000	-3,042,000	-885,000	-753,000	439,000	-609,000	-463,000	-586,000	-760,000	-490,000	-245,000	1,442,000	1,267,000	1,641,000	447,000	644,000		465,000	460,000	711,000	706,000	800,000	929,000		882,000	734,000	457,000		293,000	553,000	252,000	270,000	253,000
inventories	323,309,000	317,936,000	306,063,000	310,527,000	298,224,000	302,733,000	303,871,000	303,923,000	305,943,000	289,581,000	265,991,000	246,660,000	233,154,000	231,451,000	221,922,000	208,081,000	194,524,000	200,308,000	198,019,000	209,109,000	221,417,000	227,776,000	225,698,000	216,766,000	202,994,000	198,922,000	-28,172,000	-19,375,000	-7,189,000	-5,388,000	-17,834,000	-9,922,000	-2,160,000	844,000	-3,656,000	220,000	-1,403,000	-2,272,000	-13,113,000	3,518,000	-9,396,000	-10,553,000	-4,094,000	-2,352,000	2,334,000	3,039,000	2,149,000	-8,965,000	-8,884,000	-9,314,000	66,557,000	60,353,000	58,356,000	47,219,000	46,818,000		48,036,000	46,308,000	42,953,000	38,399,000	36,274,000	34,623,000	5,056,000	36,794,000	38,373,000	38,960,000		37,752,000	35,756,000	33,607,000	29,699,000	26,715,000	24,493,000	23,496,000	22,888,456
prepaid expenses and other current assets	30,162,000	25,007,000	28,544,000	27,105,000	26,179,000	24,437,000	24,286,000	27,954,000	24,971,000	19,961,000	22,324,000	27,388,000	23,050,000	19,809,000	16,149,000	18,778,000	16,541,000	13,617,000	13,120,000	15,579,000	13,860,000	16,284,000	12,497,000	17,610,000			-2,000,000	-2,719,000	-3,105,000	-1,223,000	-1,236,000
prepaid income taxes	3,543,000	3,417,000	3,286,000	4,216,000	4,123,000	4,088,000	4,016,000	3,936,000	3,920,000	3,920,000	3,913,000	3,515,000	3,532,000	3,547,000	3,550,000	3,679,000	3,683,000	3,680,000	3,688,000	3,545,000	3,493,000	3,486,000	3,491,000	3,611,000	3,625,000	3,620,000	-444,000	-120,000	-100,000	-72,000	-611,000	-231,000	-92,000	-89,000	404,000	-63,000	-118,000	-38,000	-1,788,000	52,000	-41,000	33,000	3,000		18,000	8,000	17,000	-367,000	2,000	-431,000
income tax refund receivables	5,785,000	80,000	2,335,000	8,185,000	4,335,000	453,000	859,000	9,432,000	4,365,000	1,069,000	779,000	4,164,000	464,000	1,803,000	2,777,000	2,561,000	3,543,000	3,331,000	3,549,000	11,812,000	10,467,000	5,586,000	3,151,000	9,566,000	4,876,000	1,317,000	232,000	134,000	-1,146,000	-205,000	-588,000	280,000	294,000	-350,000	406,000	514,000	872,000	424,000	-784,000	-539,000	11,000	10,000	24,000	192,000	1,267,000																													2,000
total current assets	923,072,000	958,635,000	923,774,000	1,078,317,000	1,162,546,000	1,105,275,000	1,108,470,000	585,318,000	594,907,000	557,217,000	529,084,000	499,863,000	492,631,000	478,092,000	482,212,000	463,442,000	449,782,000	438,488,000	429,707,000	434,626,000	445,945,000	462,508,000	454,538,000	441,302,000	426,946,000	421,783,000																									123,956,000	115,388,000	112,451,000	95,588,000	94,145,000		91,529,000	87,625,000	94,592,000	102,201,000	93,264,000	88,438,000		76,409,000	75,443,000	76,716,000		70,146,000	69,032,000	66,793,000	65,112,000	68,400,000	74,636,000	76,375,000	80,798,942
property and equipment:
land and land improvements	30,467,000	27,058,000	25,846,000	26,108,000	25,952,000	25,982,000	26,017,000	26,017,000	26,017,000	26,017,000	25,940,000	25,699,000	25,163,000	25,380,000	25,287,000	25,394,000	28,180,000	28,087,000	28,400,000	28,090,000	27,815,000	27,695,000	27,554,000	27,412,000	27,651,000	26,764,000																									15,752,000	12,579,000	10,931,000	10,932,000	10,316,000		9,776,000	7,992,000	7,992,000	7,977,000	7,977,000	7,977,000		8,107,000	8,026,000	7,958,000		7,877,000	7,885,000	6,235,000	6,166,000	5,669,000	5,667,000
buildings	198,505,000	193,561,000	192,296,000	192,323,000	191,030,000	191,218,000	191,491,000	190,825,000	189,900,000	189,947,000	189,148,000	186,976,000	188,550,000	189,773,000	190,044,000	190,335,000	188,089,000	187,774,000	188,878,000	182,914,000	181,749,000	153,896,000	153,863,000	152,782,000	153,502,000	152,974,000
manufacturing equipment	353,119,000	345,272,000	340,864,000	334,787,000	330,290,000	327,628,000	316,930,000	313,600,000	306,925,000	303,547,000	299,089,000	290,306,000	286,257,000	283,802,000	277,976,000	275,155,000	272,084,000	270,754,000	268,894,000	266,755,000	257,493,000	247,878,000	244,368,000	234,121,000	230,315,000	225,402,000																									101,660,000	94,176,000	85,572,000	83,997,000	78,965,000		75,019,000	73,640,000	70,482,000	66,797,000	65,708,000	64,487,000		61,531,000	55,656,000	55,008,000		53,266,000	50,218,000	48,164,000	42,409,000	34,243,000	33,253,000	31,155,000	30,646,287
furniture and fixtures	64,102,000	62,673,000	61,321,000	66,593,000	64,755,000	63,790,000	63,044,000	66,451,000	66,046,000	64,762,000	61,128,000	63,380,000	62,620,000	61,877,000	61,446,000	62,445,000	62,142,000	61,422,000	61,586,000	61,830,000	60,358,000	58,955,000	57,623,000	59,487,000	57,565,000	55,378,000																									21,302,000	19,091,000	17,979,000	17,215,000	16,390,000		15,550,000	15,113,000	14,336,000	18,196,000	17,811,000	17,322,000		17,456,000	17,007,000	16,585,000		17,164,000	16,941,000	16,367,000	15,262,000	13,776,000	13,190,000	12,620,000	12,430,876
leasehold improvements	60,649,000	59,447,000	58,770,000	59,005,000	58,595,000	53,772,000	53,638,000	53,208,000	52,604,000	50,826,000	49,673,000	49,962,000	48,813,000	48,060,000	46,341,000	45,750,000	47,217,000	48,319,000	48,800,000	48,549,000	44,952,000	43,950,000	43,311,000	36,992,000	34,518,000	34,221,000																									12,632,000	12,360,000	12,034,000	11,870,000	10,487,000		10,122,000	9,906,000	9,881,000	9,926,000	9,941,000	9,902,000		10,039,000	7,739,000	7,726,000		7,654,000	6,630,000	6,694,000	4,117,000	4,115,000	4,107,000	4,098,000	4,715,444
construction-in-progress	74,850,000	63,722,000	58,673,000	66,699,000	61,060,000	58,296,000	61,439,000	60,492,000	62,374,000	63,786,000	61,269,000	59,783,000	54,409,000	50,870,000	51,182,000	51,756,000	48,608,000	47,735,000	46,889,000	50,251,000	59,523,000	91,802,000	83,685,000	85,703,000	69,370,000	61,304,000																									41,517,000	21,903,000	15,964,000	11,609,000	14,371,000		11,476,000	9,219,000	9,103,000	7,932,000	6,692,000	10,619,000		8,565,000	14,315,000	11,148,000		7,874,000	8,431,000	8,270,000	13,454,000	29,464,000	21,600,000	20,859,000	12,620,085
total property and equipment	781,692,000	751,733,000	737,770,000	745,515,000	731,682,000	720,686,000	712,559,000	710,593,000	703,866,000	698,885,000	686,247,000	676,106,000	665,812,000	659,762,000	652,276,000	650,835,000	646,320,000	644,091,000	643,447,000	638,389,000	631,890,000	624,176,000	610,404,000	596,497,000	572,921,000	556,043,000
less accumulated depreciation	-371,707,000	-361,409,000	-351,605,000	-355,862,000	-345,743,000	-337,025,000	-329,036,000	-327,267,000	-319,504,000	-311,435,000	-303,271,000	-299,950,000	-294,361,000	-287,853,000	-280,618,000	-277,379,000	-272,519,000	-265,914,000	-260,719,000	-254,585,000	-248,261,000	-239,316,000	-231,619,000	-229,596,000	-222,402,000	-215,279,000																									-81,412,000
property and equipment — net	409,985,000	390,324,000	386,165,000	389,653,000	385,939,000	383,661,000	383,523,000	383,326,000	384,362,000	387,450,000	382,976,000	376,156,000	371,451,000	371,909,000	371,658,000	373,456,000	373,801,000	378,177,000	382,728,000	383,804,000	383,629,000	384,860,000	378,785,000	366,901,000	350,519,000	340,764,000
other assets:
intangible assets:
developed technology — net of accumulated amortization — 2025 — 414,713 and 2024 — 377,993	489,975,000
other — net of accumulated amortization — 2025 — 90,872 and 2024 — 85,343	72,183,000
goodwill	504,555,000	464,360,000	463,511,000	399,448,000	381,433,000	381,539,000	382,240,000	381,052,000	381,767,000	360,291,000	359,821,000	358,056,000	359,692,000	361,456,000	361,741,000	362,000,000	362,810,000	362,500,000	363,533,000	353,622,000	353,093,000	352,242,000	353,193,000	352,158,000	352,133,000	334,951,000																									61,144,000	58,659,000	54,738,000	33,002,000	33,002,000		32,849,000	32,567,000	21,124,000	11,680,000	11,680,000	11,651,000		9,099,000	9,068,000	9,684,000		8,090,000	7,579,000	6,470,000	5,750,000	5,738,000	5,717,000	4,765,000	4,764,596
deferred income tax assets	16,243,000	16,100,000	16,044,000	7,253,000	7,013,000	7,072,000	7,288,000	6,438,000	6,492,000	6,665,000	6,599,000	5,467,000	5,861,000	6,179,000	6,080,000	4,581,000	4,614,000	4,529,000	4,597,000	3,857,000	3,748,000	3,716,000	3,788,000	2,944,000	3,038,000	3,083,000																									4,591,000	4,651,000	5,005,000	3,289,000	3,287,000		2,783,000	2,781,000	2,779,000	2,083,000	2,087,000	2,087,000		3,000	3,000	163,000		28,000	28,000	24,000	41,000	41,000	38,000		677,212
right-of-use operating lease assets	89,279,000	87,722,000	65,508,000	68,867,000	69,903,000	72,639,000	63,047,000	63,633,000	62,436,000	62,881,000	65,262,000	64,700,000	64,353,000	64,659,000	65,913,000	68,078,000	70,767,000	74,714,000	78,240,000	76,775,000	79,051,000	79,133,000	80,244,000	79,757,000	79,309,000	80,453,000
other assets	80,753,000	71,856,000	65,336,000	62,382,000	61,583,000	58,682,000	54,793,000	48,545,000	52,492,000	45,721,000	44,352,000	44,388,000	43,303,000	41,707,000	41,421,000	40,672,000	37,827,000	37,286,000	37,676,000	35,011,000	36,413,000	36,569,000	41,461,000	59,735,000	58,255,000	60,052,000	315,000	-1,370,000	-751,000	-491,000	-3,735,000	-2,992,000	-1,500,000	-1,172,000	-3,763,000	-1,591,000	-762,000	109,000	-362,000	-602,000	-1,388,000	-1,128,000	-641,000	-847,000	-1,806,000	-813,000	-377,000	-1,178,000	-869,000	-283,000	8,053,000	9,664,000	7,265,000	6,592,000	6,483,000		3,030,000	2,730,000	2,181,000			2,911,000		2,844,000	2,921,000	2,830,000	102,000	2,659,000	2,424,000	2,552,000	2,254,000	1,980,000	1,856,000	1,441,000	1,268,768
total other assets	1,252,988,000	1,119,014,000	1,108,664,000	910,114,000	823,354,000	837,416,000	833,251,000	839,861,000	858,299,000	739,442,000	751,906,000	756,718,000	767,437,000	779,739,000	794,424,000	806,268,000	818,810,000	835,054,000	851,961,000	852,080,000	886,295,000	901,904,000	923,998,000	953,501,000	958,805,000	927,246,000																									132,354,000	129,447,000	129,117,000	66,552,000	66,779,000		61,908,000	61,927,000	40,810,000	21,997,000	21,576,000	21,586,000		18,468,000	17,456,000	17,306,000		15,150,000	13,701,000	12,447,000	10,879,000	10,632,000	10,477,000	8,275,000	8,266,689
total assets	2,586,045,000	2,467,973,000	2,418,603,000	2,378,084,000	2,371,839,000	2,326,352,000	2,325,244,000	1,808,505,000	1,837,568,000	1,684,109,000	1,663,966,000	1,632,737,000	1,631,519,000	1,629,740,000	1,648,294,000	1,643,166,000	1,642,393,000	1,651,719,000	1,664,396,000	1,670,510,000	1,715,869,000	1,749,272,000	1,757,321,000																												418,833,000	380,417,000	364,042,000	280,212,000	277,136,000		264,631,000	257,065,000	241,150,000	227,922,000	217,435,000	210,759,000		193,165,000	190,596,000	189,443,000		177,107,000	172,720,000	166,074,000	158,981,000	153,417,000	146,340,000	128,994,000	125,498,399
see condensed notes to consolidated financial statements.
trade receivables — net of allowance for credit losses — 2025 — 10,708 and 2024 — 9,729		199,550,000
developed technology — net of accumulated amortization — 2025 — 395,575 and 2024 — 377,993		414,348,000
other — net of accumulated amortization — 2025 — 87,986 and 2024 — 85,343		64,628,000
trade receivables — net of allowance for credit losses — 2024 — 9,729 and 2023 — 9,023			190,243,000
developed technology — net of accumulated amortization — 2024 — 377,993 and 2023 — 321,488			431,766,000
other — net of accumulated amortization — 2024 — 85,343 and 2023 — 76,887			66,499,000
see notes to consolidated financial statements.
trade receivables — net of allowance for credit losses — 2024 — 9,266 and 2023 — 9,023				189,831,000
developed technology — net of accumulated amortization — 2024 — 361,725 and 2023 — 321,488				322,325,000
other — net of accumulated amortization — 2024 — 82,979 and 2023 — 76,887				49,839,000
trade receivables — net of allowance for credit losses — 2024 — 9,276 and 2023 — 9,023					182,415,000
developed technology — net of accumulated amortization — 2024 — 346,763 and 2023 — 321,488					264,195,000
other — net of accumulated amortization — 2024 — 80,628 and 2023 — 76,887					39,227,000
trade receivables — net of allowance for credit losses — 2024 — 9,327 and 2023 — 9,023						180,663,000
developed technology — net of accumulated amortization — 2024 — 333,920 and 2023 — 321,488						277,085,000
other — net of accumulated amortization — 2024 — 78,771 and 2023 — 76,887						40,399,000
trade receivables — net of allowance for credit losses — 2023 — 9,023 and 2022 — 8,423							177,885,000
developed technology — net of accumulated amortization — 2023 — 321,488 and 2022 — 274,570							283,999,000
other — net of accumulated amortization — 2023 — 76,887 and 2022 — 69,780							41,884,000
trade receivables — net of allowance for credit losses — 2023 — 8,721 and 2022 — 8,423								167,824,000
developed technology — net of accumulated amortization — 2023 — 308,889 and 2022 — 274,570								296,349,000
other — net of accumulated amortization — 2023 — 76,909 and 2022 — 69,780								43,844,000
trade receivables — net of allowance for credit losses — 2023 — 8,652 and 2022 — 8,423									170,990,000
developed technology — net of accumulated amortization — 2023 — 296,131 and 2022 — 274,570									309,228,000
other — net of accumulated amortization — 2023 — 74,418 and 2022 — 69,780									45,884,000
trade receivables — net of allowance for credit losses — 2023 — 8,248 and 2022 — 8,423										170,182,000
developed technology — net of accumulated amortization — 2023 — 285,008 and 2022 — 274,570										227,203,000
other — net of accumulated amortization — 2023 — 71,742 and 2022 — 69,780										36,681,000
trade receivables — net of allowance for credit losses — 2022 — 8,423 and 2021 — 6,767											164,677,000
developed technology — net of accumulated amortization — 2022 — 274,570 and 2021 — 234,016											237,522,000
other — net of accumulated amortization — 2022 — 69,780 and 2021 — 65,053											38,350,000
trade receivables — net of allowance for credit losses — 2022 — 8,018 and 2021 — 6,767												155,828,000
developed technology — net of accumulated amortization — 2022 — 263,990 and 2021 — 234,016												245,282,000
other — net of accumulated amortization — 2022 — 68,308 and 2021 — 65,053												38,825,000
trade receivables — net of allowance for credit losses — 2022 — 7,738 and 2021 — 6,767													158,801,000
developed technology — net of accumulated amortization — 2022 — 254,031 and 2021 — 234,016													254,557,000
other — net of accumulated amortization — 2022 — 66,591 and 2021 — 65,053													39,671,000
trade receivables — net of allowance for credit losses — 2022 — 7,568 and 2021 — 6,767														155,859,000
developed technology — net of accumulated amortization — 2022 — 244,017 and 2021 — 234,016														264,839,000
other — net of accumulated amortization — 2022 — 66,924 and 2021 — 65,053														40,899,000
trade receivables — net of allowance for credit losses — 2021 — 6,767 and 2020 — 5,313															152,301,000
developed technology — net of accumulated amortization — 2021 — 234,016 and 2020 — 193,164															276,833,000
other — net of accumulated amortization — 2021 — 65,053 and 2020 — 56,943															42,436,000
trade receivables — net of allowance for credit losses — 2021 — 6,444 and 2020 — 5,313																150,780,000
developed technology — net of accumulated amortization —2021 — 223,814 and 2020 — 193,164																287,117,000
other — net of accumulated amortization — 2021 — 63,030 and 2020 — 56,943																43,820,000
trade receivables — net of allowance for credit losses — 2021 — 5,652 and 2020 — 5,313																	153,443,000
developed technology — net of accumulated amortization —2021 — 213,621 and 2020 — 193,164																	297,471,000
other — net of accumulated amortization — 2021 — 60,993 and 2020 — 56,943																	45,321,000
trade receivables — net of allowance for credit losses — 2021 — 5,953 and 2020 — 5,313																		150,314,000
developed technology — net of accumulated amortization —2021 — 203,308 and 2020 — 193,164																		307,713,000
other — net of accumulated amortization — 2021 — 59,025 and 2020 — 56,943																		48,312,000
trade receivables — net of allowance for credit losses — 2020 — 5,313 and 2019 — 3,108																			146,641,000
developed technology — net of accumulated amortization —2020 — 193,164 and 2019 — 149,947																			318,059,000
other — net of accumulated amortization — 2020 — 56,943 and 2019 — 65,607																			49,856,000
assets
trade receivables — net of allowance for uncollectible accounts — 2020 — 4,687 and 2019 — 3,108																				141,957,000
developed technology — net of accumulated amortization —2020 — 182,148 and 2019 — 149,947																				331,851,000
other — net of accumulated amortization — 2020 — 56,913 and 2019 — 65,607																				50,964,000
trade receivables — net of allowance for uncollectible accounts — 2020 — 3,866 and 2019 — 3,108																					138,792,000
developed technology — net of accumulated amortization —2020 — 174,495 and 2019 — 149,947																					354,273,000
other — net of accumulated amortization — 2020 — 59,926 and 2019 — 65,607																					59,717,000
trade receivables — net of allowance for uncollectible accounts — 2020 — 4,124 and 2019 — 3,108																						150,050,000
developed technology — net of accumulated amortization —2020 — 162,135 and 2019 — 149,947																						366,551,000
other — net of accumulated amortization — 2020 — 59,934 and 2019 — 65,607																						63,693,000
trade receivables — net of allowance for uncollectible accounts — 2019 — 3,108 and 2018 — 2,355																							155,365,000
developed technology — net of accumulated amortization —2019 — 149,947 and 2018 — 102,357																							379,529,000
other — net of accumulated amortization — 2019 — 65,607 and 2018 — 49,136																							65,783,000
trade receivables — net of allowance for uncollectible accounts — 2019 — 2,848 and 2018 — 2,355																								144,683,000
developed technology — net of accumulated amortization —2019 — 137,551 and 2018 — 102,357																								390,796,000
other — net of accumulated amortization — 2019 — 62,378 and 2018 — 49,136																								68,111,000
total																								1,761,704,000	1,736,270,000	1,689,793,000																									243,935,000	210,508,000	192,617,000	185,391,000	180,824,000		171,943,000	165,773,000	161,659,000	160,234,000	157,254,000	153,548,000		148,809,000	145,802,000	141,462,000		136,392,000	132,638,000	128,217,000	120,991,000	110,969,000	96,657,000	77,510,000	68,510,443
trade receivables — net of allowance for uncollectible accounts — 2019 — 2,656 and 2018 — 2,355																									156,444,000
prepaid expenses and current other assets																									12,305,000	11,220,000
developed technology — net of accumulated amortization — 2019 — 125,447 and 2018 — 102,357																									391,651,000
other — net of accumulated amortization — 2019 — 56,289 and 2018 — 49,136																									74,419,000
merit medical systems, inc. and subsidiariesconsolidated balance sheetsjune 30, 2019 and december 31, 2018
liabilities and stockholders’ equity																																																																					2,006,000
current liabilities:
trade payables																									52,601,000	51,680,000	15,726,000	15,936,000	15,767,000	8,409,000	417,000	-876,000	3,664,000	1,039,000	-6,835,000	-9,018,000	-5,147,000	2,400,000	14,766,000	84,000	5,326,000	655,000	2,299,000	-485,000	-5,000	586,000	-2,084,000	7,721,000	5,805,000	-2,129,000						296,000	13,570,000	14,304,000	13,191,000		11,709,000	11,246,000		10,158,000	11,140,000	11,818,000	305,000	11,270,000	10,758,000	10,427,000	12,506,000	13,054,000	12,359,000	8,727,000	8,600,311
accrued expenses																									97,176,000	91,310,000	12,706,000	7,707,000	7,467,000	-2,395,000	6,461,000	4,514,000	7,833,000	3,285,000	3,245,000	1,693,000	3,039,000	-3,936,000	5,656,000	2,653,000	6,137,000	4,686,000	3,539,000	2,868,000	-276,000	-3,705,000	-2,280,000	4,448,000	2,793,000	1,334,000						1,628,000	13,213,000	12,182,000	11,553,000		10,856,000	9,821,000	872,000	9,880,000	9,794,000	8,684,000		8,827,000	9,853,000	8,549,000	9,121,000	8,651,000	7,667,000	7,385,000	7,884,561
current portion of long-term debt																									15,000,000	22,000,000																																										1,000	1,000	1,000	2,000	4,000	5,000
short-term operating lease liabilities																									11,732,000
income taxes payable																									42,000	1,644,000	918,000	-1,528,000	-2,076,000	-480,000	21,000	-764,000	-301,000	-22,000	1,451,000	-183,000	1,620,000	578,000	2,199,000	1,377,000	1,083,000	3,248,000	759,000	91,000	255,000	-1,319,000	-34,000	2,057,000	2,670,000	2,658,000						825,000	1,472,000	2,161,000	2,109,000		846,000	2,334,000	1,595,000	138,000	401,000	819,000	2,724,000	1,541,000	1,448,000	1,223,000	1,016,000	1,578,000	3,237,000	1,076,000	2,239,977
total current liabilities																									176,551,000	178,459,000																															35,660,000	36,075,000	27,167,000		25,252,000	25,162,000		20,487,000	21,647,000	21,553,000		22,662,000	23,053,000	20,995,000	23,645,000	24,064,000	23,863,000	17,335,000	18,932,946
long-term debt																									385,221,000	362,187,000																																										3,000	3,000	4,000	3,000	5,000	5,000
deferred income tax liabilities																									60,932,000	56,324,000																															8,788,000	8,789,000	8,782,000		6,511,000	6,533,000		97,000	4,812,000	4,344,000		812,000	720,000	568,000	768,000	503,000	449,000	2,991,000	3,218,893
long-term income taxes payable																									392,000	392,000	-4,454,000				4,846,000
liabilities related to unrecognized tax benefits																									3,013,000	3,013,000	267,000				-19,000				597,000	-366,000			536,000		-76,000	-844,000	-264,000		-520,000			-209,000	-993,000	-226,000
deferred compensation payable																									12,739,000	12,480,000	39,000	994,000	438,000	3,000	1,970,000	1,107,000	513,000	187,000	712,000	500,000	603,000	-305,000	-135,000	473,000	802,000	644,000	532,000	282,000	1,877,000	647,000	281,000	1,371,000	838,000	327,000						1,034,000	3,048,000	2,736,000	2,205,000		3,207,000	3,048,000		2,893,000	3,022,000	2,950,000		2,594,000	2,586,000	2,588,000	2,211,000	2,064,000	1,918,000	1,470,000	1,281,982
deferred credits																									2,192,000	2,227,000																															1,903,000	1,931,000	1,967,000		2,052,000	2,078,000		2,134,000	2,167,000	2,200,000		2,280,000	2,325,000	2,370,000	2,462,000	2,510,000	2,561,000	1,352,000	1,404,884
long-term operating lease liabilities																									71,272,000
other long-term obligations																									73,283,000	62,357,000	-801,000	-1,381,000	-179,000	-337,000	2,510,000	574,000	907,000	790,000	-200,000	-251,000	-212,000	-76,000	1,769,000	433,000	566,000	764,000	446,000	-50,000	-4,399,000	-127,000	294,000	-89,000	314,000	-70,000							461,000	386,000	395,000		371,000			435,000	528,000
total liabilities																									785,595,000	749,682,000																															52,541,000	52,735,000	43,334,000		39,981,000	39,798,000		34,878,000	36,033,000	34,917,000		31,735,000	32,186,000	30,188,000	30,927,000	31,133,000	30,897,000	23,148,000	24,838,705
commitments and contingencies
stockholders’ equity:
preferred stock — 5,000 shares authorized as of june 30, 2019 and december 31, 2018; no shares issued
common stock																									579,250,000	574,946,000
retained earnings																									376,572,000	369,713,000																															150,137,000	144,052,000	138,211,000		122,082,000	116,264,000		107,220,000	102,925,000	99,329,000		93,916,000	90,591,000	87,069,000	80,974,000	77,647,000	72,965,000	64,594,000	60,405,915
accumulated other comprehensive loss																									-5,147,000	-4,548,000
total stockholders’ equity																									950,675,000	940,111,000																															212,090,000	204,330,000	197,816,000		177,454,000	170,961,000		158,287,000	154,563,000	154,526,000		145,372,000	140,534,000	135,886,000	128,054,000	122,284,000	115,443,000	105,846,000	100,659,694
trade receivables — net of allowance for uncollectible accounts — 2019 — 2,406 and 2018 — 2,355																										146,488,000
developed technology — net of accumulated amortization — 2019 — 113,765 and 2018 — 102,357																										371,603,000
other — net of accumulated amortization — 2019 — 52,469 and 2018 — 49,136																										77,104,000
merit medical systems, inc. and subsidiariesconsolidated balance sheetsmarch 31, 2019 and december 31, 2018
short-term operating lease liability																										11,825,000
long-term operating lease liability																										72,243,000
preferred stock — 5,000 shares authorized as of march 31, 2019 and december 31, 2018; no shares issued
cash flows from operating activities:
net income																											42,017,000	32,828,000	16,210,000	5,269,000	27,523,000	20,717,000	24,286,000	14,803,000	20,121,000	12,615,000	11,641,000	4,351,000	23,802,000	5,174,000	22,974,000	14,303,000	6,539,000	2,823,000	16,570,000	4,423,000	671,000	19,710,000	19,069,000	23,044,000						22,530,000							15,588,000				12,301,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization																											69,546,000	50,436,000	32,779,000	15,284,000	53,582,000	39,388,000	25,709,000	12,759,000	43,755,000	31,594,000	19,705,000	9,705,000	37,425,000	9,068,000	35,929,000	26,719,000	17,593,000	8,702,000	32,542,000	15,729,000	7,683,000	22,534,000	16,724,000	19,194,000						12,271,000							9,444,000				8,275,000
gain on bargain purchase																															-11,039,000	-10,796,000	-11,574,000	-12,243,000
losses on sales and/or abandonment of property and equipment																											625,000					219,000	234,000	212,000		102,000	44,000	29,000		37,000	916,000	549,000		91,000	177,000			204,000		31,000						271,000							317,000				242,000
write-off of patents and intangible assets																											814,000	744,000	86,000	57,000	988,000	86,000	19,000	18,000	101,000	90,000	90,000		141,000	14,000	1,427,000	1,360,000		34,000	8,208,000
acquired in-process research and development																											644,000	382,000	306,000		12,136,000	12,136,000	75,000		461,000	400,000	100,000		1,000,000									2,450,000	2,450,000	5,838,000
amortization of deferred credits																											-142,000	-106,000	-71,000	-36,000	-147,000	-111,000	-76,000	-40,000	-170,000	-128,000	-85,000	-43,000	-171,000	-43,000	-175,000	-131,000	-88,000	-45,000	-139,000	-64,000	-32,000	-174,000	-140,000	-106,000
amortization of long-term debt issuance costs																											804,000	603,000	402,000	201,000	685,000	514,000	343,000	171,000	952,000	779,000	521,000	257,000	987,000	247,000	987,000	741,000	494,000	247,000	845,000	399,000	199,000
deferred income taxes																											2,052,000				-1,304,000	-290,000	-295,000	-387,000	-962,000	187,000	141,000	170,000	3,450,000	462,000	3,870,000	-184,000	19,000	21,000	1,359,000	-6,000	2,000	549,000	14,000	1,677,000						1,791,000							984,000				376,000
excess tax benefits from stock-based compensation																																			-669,000	-527,000	12,000	3,000	-2,124,000	-860,000	-576,000	-243,000	-236,000	-168,000	-259,000	-124,000	53,000	-877,000	716,000	3,122,000
stock-based compensation expense																											6,117,000	4,494,000	2,821,000	1,256,000	4,075,000	2,883,000	1,691,000	577,000	2,506,000	1,913,000	1,410,000	624,000	2,243,000	520,000	1,460,000	1,004,000	663,000	339,000	1,467,000	783,000	459,000	1,917,000	1,454,000	1,644,000						1,182,000
changes in operating assets and liabilities, net of effects from acquisitions:
trade receivables																											-27,522,000	-25,482,000	-27,947,000	-13,166,000	-12,844,000	-10,963,000	-13,248,000	-5,757,000	-6,816,000	-5,166,000	-6,459,000	-835,000	-5,872,000	-2,334,000	-13,599,000	-9,198,000	-7,152,000	-4,115,000	-6,445,000	-5,190,000	-1,473,000	-6,576,000	-7,521,000	-3,323,000																	57,000
total adjustments																											44,516,000	30,029,000	18,839,000	2,666,000	35,204,000	22,676,000	10,280,000	375,000	33,478,000	23,723,000	13,803,000	7,232,000	45,656,000	14,098,000	30,351,000	17,282,000	13,600,000	5,137,000	34,803,000	9,942,000	2,222,000	27,228,000	13,093,000	10,971,000						7,540,000							16,531,000				6,805,000
net cash from operating activities																											86,533,000	62,857,000	35,049,000	7,935,000	62,727,000	43,393,000	34,566,000	15,178,000	53,599,000	36,338,000	25,444,000	11,583,000	69,458,000	19,272,000	53,325,000	31,585,000	20,139,000	7,960,000	51,373,000	14,365,000	2,893,000	46,938,000	32,162,000	34,015,000						30,070,000							32,119,000				19,106,000
cash flows from investing activities:
capital expenditures for:
property and equipment																											-63,324,000	-47,024,000	-31,559,000	-16,239,000	-38,623,000	-29,522,000	-17,782,000	-10,178,000	-32,837,000	-26,492,000	-21,222,000	-10,991,000	-50,959,000	-9,492,000	-34,181,000	-24,262,000	-18,716,000	-8,708,000	-59,505,000	-30,389,000	-19,961,000	-64,643,000	-49,264,000	-59,195,000
intangible assets																											-3,012,000	-2,234,000	-1,755,000	-885,000	-2,577,000	-1,927,000	-1,082,000	-668,000	-2,217,000	-1,594,000	-989,000	-482,000	-1,956,000	-495,000	-1,714,000	-1,368,000	-925,000	-433,000	-1,617,000			-1,460,000
proceeds from sale of cost method investment																																			1,089,000	1,089,000	1,089,000	1,089,000
proceeds from the sale of property and equipment																											55,000	7,000	4,000	3,000	21,000	9,000	3,000	3,000	19,000	5,000			1,247,000	3,000	98,000	62,000	21,000	18,000	113,000	53,000	8,000	43,000	9,000	5,000						27,000							11,000				27,000
issuance of notes receivable																											-10,750,000
cash paid in acquisitions, net of cash acquired																											-301,789,000	-122,770,000	-118,654,000	-100,195,000	-105,582,000	-103,500,000	-54,809,000	-47,461,000	-125,161,000	-119,808,000	-22,800,000	-21,500,000	-12,368,000	-1,250,000	-5,927,000	-4,202,000	-1,450,000		-31,600,000			-192,762,000		-10,250,000
net cash from investing activities																											-378,820,000	-182,771,000	-162,464,000	-117,316,000	-146,761,000	-134,940,000	-73,670,000	-58,304,000	-159,107,000	-146,800,000	-43,922,000	-31,884,000	-62,019,000	-9,411,000	-36,203,000	-26,586,000	-21,070,000	-9,123,000	-68,609,000	-31,997,000	-21,347,000	-255,574,000	-70,621,000	-74,020,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2018, 2017 and 2016
cash flows from financing activities:
proceeds from issuance of common stock																											214,993,000	213,276,000	3,251,000	1,511,000	143,810,000	143,069,000	140,989,000	138,569,000	5,271,000	4,422,000	791,000	557,000	6,668,000	4,021,000	8,146,000	3,811,000	3,528,000	803,000	3,729,000	876,000	571,000	3,755,000	3,326,000	95,454,000
offering costs																											-366,000	-366,000			-816,000
proceeds from issuance of long-term debt																											639,108,000	380,825,000	320,827,000	256,971,000	197,214,000	151,462,000	96,859,000	83,723,000	219,505,000	203,478,000	93,812,000	55,184,000	152,375,000	31,803,000	144,018,000	108,782,000	71,734,000	36,010,000	176,764,000			330,630,000		104,585,000
payments on long-term debt																											-522,608,000	-450,575,000	-185,827,000	-148,971,000	-243,214,000	-197,962,000	-179,359,000	-170,723,000	-102,098,000	-82,658,000	-69,687,000	-34,376,000	-169,272,000	-43,415,000	-169,392,000	-117,772,000	-72,213,000	-30,423,000	-165,477,000	-51,910,000	-17,512,000	-123,801,000	-94,151,000	-155,386,000
long-term debt issuance costs																															-416,000				-1,948,000	-1,948,000									-798,000			-3,706,000
contingent payments related to acquisitions																											-231,000	-184,000	-130,000	-15,000	-61,000	-45,000	-30,000	-15,000	-218,000	-199,000	-183,000	-167,000	-1,212,000	-166,000	-67,000	-55,000	-38,000	-24,000	-77,000	-38,000	-19,000	-57,000	-36,000
payment of taxes related to an exchange of common stock																											-2,616,000	-2,616,000							-86,000	-86,000			-918,000	-380,000	-249,000	-220,000	-220,000	-220,000	-21,000	-21,000		-439,000	-287,000	-953,000
net cash from financing activities																											328,280,000	140,360,000	138,121,000	109,496,000	96,517,000	95,708,000	57,644,000	50,721,000	121,095,000	123,536,000	24,721,000	21,195,000	-10,235,000	-7,277,000	-16,968,000	-5,211,000	3,027,000	6,314,000	14,768,000	20,953,000	18,042,000	208,288,000	37,806,000	46,695,000
effect of exchange rates on cash																											-970,000	-827,000	470,000	1,720,000	682,000	30,000	-36,000	-302,000	-593,000	67,000	67,000	91,000	-382,000	-31,000	-258,000	-809,000	-154,000	-19,000	208,000	103,000	-290,000	-61,000	-10,000	-297,000
net increase in cash and cash equivalents																											35,023,000	19,619,000	11,176,000	1,835,000	13,165,000	4,191,000	18,504,000	7,293,000	14,994,000	13,141,000	6,310,000	985,000		2,553,000			1,942,000	5,132,000	-2,260,000	3,424,000		-409,000	-663,000	6,393,000
cash and cash equivalents:
beginning of year																											32,336,000				19,171,000				4,177,000				7,355,000		7,459,000				9,719,000			10,128,000		3,735,000
end of year																											67,359,000				32,336,000				19,171,000				4,177,000		7,355,000				7,459,000			9,719,000		10,128,000
supplemental disclosures of cash flow information
cash paid during the year for:
interest																											10,324,000	8,018,000	5,714,000	2,383,000	7,707,000	5,953,000	4,386,000	2,743,000	8,872,000	6,223,000	2,912,000	1,378,000	6,273,000	1,254,000	9,014,000	7,204,000	4,969,000	2,644,000	7,877,000	2,970,000	1,493,000	434,000	238,000	509,000
income taxes																											8,692,000	6,069,000	5,141,000	1,810,000	6,049,000	4,029,000	2,678,000	1,571,000	2,318,000	2,237,000	1,580,000	428,000	3,409,000	931,000	3,289,000	2,679,000	1,911,000	782,000	735,000	1,071,000	403,000	5,277,000	4,629,000	7,023,000
supplemental disclosures of non-cash investing and financing activities
property and equipment purchases in accounts payable																											4,989,000	3,058,000	3,943,000	1,752,000	1,992,000	1,394,000	1,560,000	756,000	2,398,000	2,709,000	1,497,000	1,584,000	3,199,000	1,743,000	2,896,000	3,853,000	3,433,000	5,180,000	4,055,000	12,372,000	5,354,000	12,372,000	7,429,000	8,849,000
contingent receivable in exchange for sale of equity investment
receivable for issuance of common stock associated with option exercises																															137,000
acquisition purchases in accrued expenses and other long-term obligations																											72,209,000				10,488,000	12,000,000	6,000,000			293,000			1,300,000		1,000,000				350,000			5,149,000	5,000,000
merit common stock surrendered (43, 0 and 14 shares, respectively) in exchange for exercise of stock options																											2,261,000
loss on sales and/or abandonment of property and equipment																												425,000	371,000	351,000																	7,000
issuance of note receivable																												-10,750,000	-10,500,000
merit medical systems, inc. and subsidiaries
consolidated statements of cash flows
for the nine months ended september 30, 2018 and 2017
beginning of period																												32,336,000	32,336,000	32,336,000		19,171,000	19,171,000	19,171,000		4,177,000	4,177,000	4,177,000		7,355,000		7,459,000	7,459,000	7,459,000		9,719,000	9,719,000		10,128,000
end of period																												51,955,000	43,512,000	34,171,000		23,362,000	37,675,000	26,464,000		17,318,000	10,487,000	5,162,000		9,908,000		6,438,000	9,401,000	12,591,000		13,143,000	9,017,000		9,465,000
cash paid during the period for:
merit common stock surrendered (43 and 0 shares, respectively) in exchange for exercise of stock options																												2,262,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2018 and 2017
merit common stock surrendered (32 and 0 shares, respectively) in exchange for exercise of stock options																													1,684,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2018 and 2017
losses (gains) on sales and/or abandonment of property and equipment																															427,000				530,000				-23,000				289,000
proceeds from sale-leaseback transactions																																							2,017,000	1,823,000	5,521,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2017, 2016 and 2015
cost method investment converted to intangible asset in acquisition in lieu of additional cash payment																																							1,010,000
contingent receivable in exchange for sale of cost method investment																																			711,000
merit common stock surrendered (0, 14 and 185 shares, respectively) in exchange for exercise of stock options
fair value changes in contingent liabilities/assets																																				99,000
employee receivables																																54,000	54,000	36,000	15,000	42,000	51,000	-43,000	-52,000	-6,000	46,000	44,000	44,000	35,000	-53,000	-27,000	-18,000	-11,000	-78,000	-62,000	199,000	161,000	133,000	145,000	129,000		171,000	139,000	115,000	118,000	130,000	161,000	52,000	119,000	133,000	183,000		164,000	160,000	116,000	143,000	114,000
prepaid expenses and other assets																																-1,587,000	-1,230,000	229,000																	4,302,000	3,988,000	2,946,000	3,047,000	2,238,000		1,832,000	1,959,000	1,184,000	1,482,000	1,655,000	1,072,000		1,463,000	1,702,000	1,241,000	6,000	1,568,000	1,695,000	1,086,000	1,278,000	1,243,000	741,000	1,071,000	1,082,323
advances from employees																																-44,000	-412,000	-86,000	-3,000	-50,000	-119,000	-388,000	217,000	439,000	142,000	599,000	371,000	509,000	-277,000	142,000	90,000	317,000	408,000	-65,000							405,000	428,000	314,000		341,000	261,000	11,000	214,000	312,000	232,000		211,000	273,000	227,000	232,000	274,000	146,000	132,000	208,097
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2017 and 2016
payment of offering costs related to issuance of common stock																																-816,000	-815,000	-833,000																-127,000
merit common stock surrendered (0 and 14 shares, respectively) in exchange for exercise of stock options
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2017 and 2016
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2017 and 2016
prepaid expenses																																			271,000	-452,000	-2,226,000	-498,000	-696,000	-160,000	-58,000	-608,000	-366,000	-651,000	-758,000	-669,000	-1,242,000	736,000	-598,000	-1,726,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2016, 2015 and 2014
receivable due for sale of equipment																																									1,256,000
merit common stock surrendered (14, 185 and 127 shares, respectively) in exchange for exercise of stock options																																			346,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2016 and 2015
supplemental disclosure of non-cash investing and financing activities
contingent receivable received in exchange for sale of cost method investment																																				711,000	681,000	681,000
merit common stock surrendered (14 and 185 shares, respectively) in exchange for exercise of stock options																																				346,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2016 and 2015
acquisition purchases in accrued expenses
merit common stock surrendered (0 and 166 shares, respectively) in exchange for exercise of stock options
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2016 and 2015
merit common stock surrendered (0 and 89 shares, respectively) in exchange for exercise of stock options
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2015, 2014 and 2013
proceeds from industrial assistant grants																																													389,000	750,000	750,000	1,029,000	324,000
net decrease in cash and cash equivalents																																							-3,178,000			-1,021,000					-702,000
merit common stock surrendered (185, 127 and 45 shares, respectively) in exchange for exercise of stock options																																							3,802,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2015 and 2014
merit common stock surrendered (89 and 108 shares, respectively) in exchange for exercise of stock options																																								1,725,000
impairment of cost-method investment																																																2,368,000
realized gain on sale of marketable securities																																																-745,000	-745,000
proceeds from the sale of marketable securities																																																3,248,000	3,248,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2014, 2013 and 2012
net (decrease) in cash and cash equivalents																																									-104,000
acquisition of customer list in exchange for a settlement of trade receivables																																																377,000	378,000
merit common stock surrendered (127, 45 and 131 shares, respectively) in exchange for exercise of stock options																																									1,941,000
proceeds from sale-leaseback transaction																																										3,184,000			24,000,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2014 and 2013
merit common stock surrendered (108 and 45 shares, respectively) in exchange for exercise of stock options																																										1,641,000	1,641,000
write-off of patents																																											119,000			53,000	2,000		27,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2014 and 2013
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2014 and 2013
merit common stock surrendered (108 and 0 shares, respectively) in exchange for exercise of stock options																																												1,641,000
purchase of marketable securities																																																		-2,503,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2013, 2012 and 2011
merit common stock surrendered (45, 131 and 78 shares, respectively) in exchange for exercise of stock options																																													452,000
gain on sales and/or abandonment of property and equipment																																														-10,000
changes in fair value of contingent consideration liability related to acquisitions																																																	370,000
income tax refund receivable																																														1,073,000	-782,000	452,000	259,000	-733,000						319,000																			28,227
patents and trademarks																																														-661,000	-394,000		-1,059,000	-2,077,000
cash paid in acquisitions																																														-1,000,000	-1,000,000		-23,555,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2013 and 2012
borrowings under long-term debt																																														71,172,000	34,199,000		127,914,000
supplemental disclosures of cash flow information —
supplemental disclosures of non-cash investing and financing activities:
merit common stock surrendered (45 and 103 shares, respectively) in exchange for exercise of stock options																																														452,000
excess tax benefit from stock-based compensation																																															-53,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2013 and 2012
write-off of patents and license agreement																																																55,000		103,000
goodwill impairment charge
purchase of trading investments
unrealized gains on trading investments
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2012, 2011 and 2010
borrowings on line of credit
payments on line of credit
merit common stock surrendered (131, 78 and 0 shares, respectively) in exchange for exercise of stock options																																																1,831,000
(gain) loss on sales and/or abandonment of property and equipment																																																	-1,000
tax benefit attributable to appreciation of common stock options exercised																																																	-716,000	-3,122,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2012 and 2011
merit common stock surrendered (71 and 103 shares, respectively) in exchange for exercise of stock options																																																	1,032,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2011, 2010 and 2009
common stock repurchased and retired
acquisition purchases in other long term obligations																																																		1,270,000
merit common stock surrendered (78, 0 and 27 shares, respectively) in exchange for exercise of stock options																																																		1,252,000
trade receivables - net of allowances of 473 and 593, respectively																																																			40,579,000
income tax refunds receivable																																																			467,000	472,000	428,000	177,000	267,000		667,000	651,000	626,000	1,108,000	350,000	418,000		105,000	188,000	81,000		19,000	46,000	22,000
building																																																			51,072,000	50,399,000	50,137,000	49,768,000	50,295,000		50,000,000	49,903,000	49,865,000	49,406,000	49,125,000	43,241,000		43,111,000	43,059,000	43,037,000		42,557,000	42,533,000	42,487,000	39,583,000	23,702,000	18,840,000	5,950,000	5,269,821
property and equipment—net																																																			162,523,000	135,582,000	122,474,000	118,072,000	116,212,000		111,194,000	107,513,000	105,748,000	103,724,000	102,595,000	100,735,000		98,288,000	97,697,000	95,421,000		91,811,000	89,987,000	86,834,000	82,990,000	74,385,000	61,227,000	44,344,000	36,432,768
intangibles - net of accumulated amortization of 13,498 and 8,996, respectively																																																			58,544,000
trade receivables - net of allowances of 492 and 593, respectively																																																				41,031,000
intangibles - net of accumulated amortization of 10,573 and 8,996, respectively																																																				56,828,000
trade receivables - net of allowances of 660 and 541, respectively																																																					38,644,000
other intangibles - net of accumulated amortization of 7,754 and 5,450, respectively																																																					59,796,000
trade receivables - net of allowances of 599 and 541, respectively																																																						37,010,000
other intangibles - net of accumulated amortization of 6,782 and 5,450, respectively																																																						26,958,000
trade receivables - net of allowances of 487 and 541, respectively																																																							34,770,000
intangibles - net of accumulated amortization of 6,120 and 5,450, respectively																																																							27,294,000
write-off of certain patents and license agreement																																																								154,000
proceeds from sale of trading investments
unrealized (gains) losses on trading investments
changes in operating assets and liabilities net of effects from acquisitions:
current liabilities related to unrecognized tax positions																																																															1,023,000
non-current liabilities related to unrecognized tax positions																																																								114,000
trade receivables - net of allowances of 650 and 505, respectively																																																									31,812,000
other intangibles - net of accumulated amortization of 4,720 and 3,122, respectively																																																									25,899,000
deposits																																																									92,000	91,000	126,000	73,000	78,000	78,000	12,000	84,000	84,000	84,000	9,000	96,000	99,000	99,000	128,000	156,000	137,000	127,000	126,874
other payables																																																									7,000,000	7,000,000			1,500,000	1,500,000
liabilities related to unrecognized tax positions																																																									2,681,000	2,818,000	2,818,000		2,588,000	2,588,000		3,388,000	3,857,000	3,692,000
preferred stock—5,000 shares authorized as of september 30, 2009 and december 31, 2008; no shares issued
common stock—no par value; 100,000 shares authorized; 28,059 and 28,093 shares issued at september 30, 2009 and december 31, 2008, respectively																																																									62,012,000
total liabilities and stockholders’ equity																																																									264,631,000	257,065,000	241,150,000		217,435,000	210,759,000		193,165,000	190,596,000	189,443,000		177,107,000	172,720,000	166,074,000	158,981,000	153,417,000	146,340,000	128,994,000	125,498,399
trade receivables - net of allowances of 621 and 505, respectively																																																										30,454,000
other intangibles - net of accumulated amortization of 3,986 and 3,122, respectively																																																										26,503,000
preferred stock—5,000 shares authorized as of june 30, 2009 and december 31, 2008; no shares issued
common stock—no par value; 100,000 shares authorized; 27,943 and 28,093 shares issued at june 30, 2009 and december 31 2008, respectively																																																										60,343,000
trade receivables - net of allowances of 636 and 505, respectively																																																											29,794,000
other intangibles - net of accumulated amortization of 3,421 and 3,122, respectively																																																											17,344,000
preferred stock—5,000 shares authorized as of march 31, 2009 and december 31, 2008; no shares issued
common stock—no par value; 100,000 shares authorized; 27,916 and 28,093 shares issued at march 31, 2009 and december 31 2008, respectively																																																											59,732,000
marketable securities																																																												894,000
trade receivables - net of allowances of 460 and 497, respectively																																																												26,330,000
less accumulated depreciation and amortization
other intangibles - net of accumulated amortization of 2,891 and 2,171, respectively																																																												6,998,000
deferred compensation investments																																																												2,910,000
trade receivables - net of allowances of 515 and 497, respectively																																																													25,212,000
other intangibles - net of accumulated amortization of 2,671 and 2,171, respectively																																																													6,429,000
deferred compensation assets																																																													3,053,000
preferred stock—5,000 shares authorized as of june 30, 2008, no shares issued
common stock—no par value; 50,000 shares authorized; 27,635 and 27,413 shares issued at june 30, 2008 and december 31 2007, respectively																																																													55,272,000
accumulated other comprehensive income																																																													100,000	133,000
trade receivables - net of allowances of 511 and 497, respectively																																																														25,391,000
other intangibles - net of accumulated amortization of 2,396 and 2,171, respectively																																																														6,610,000
other long-term obligation																																																														389,000				178,000		62,000	75,000	87,000
preferred stock—5,000 shares authorized as of march 31, 2008, no shares issued
common stock—no par value; 50,000 shares authorized; 27,589 and 27,413 shares issued at march 31, 2008 and december 31 2007, respectively																																																														54,564,000
impairment of assets																																																																			929,000
write-off of certain patents and trademarks																																																															245,000				40,000
stock-based compensation																																																															1,130,000				1,502,000
other long-term assets
increase in cash surrender value of life insurance contracts
cash paid in acquisitions—net of cash acquired
trade receivables - less allowances of 530 and 560, respectively																																																																24,844,000
other intangibles - less accumulated amortization of 2,085 and 1,519, respectively																																																																6,438,000
preferred stock—5,000 shares authorized as of september 30, 2007, no shares issued
common stock—no par value; 50,000 shares authorized; 27,304 and 27,647 shares issued at september 30, 2007 and december 31, 2006, respectively																																																																51,088,000
trade receivables - less allowances of 518 and 560, respectively																																																																	25,029,000
other intangibles - less accumulated amortization of 1,897 and 1,519, respectively																																																																	5,369,000
preferred stock—5,000 shares authorized as of june 30, 2007, no shares issued
common stock—no par value; 50,000 shares authorized; 27,383 and 27,647 shares issued at june 30, 2007 and december 31, 2006, respectively																																																																	51,755,000
trade receivables - less allowances of 544 and 560, respectively																																																																		25,986,000
other intangibles - less accumulated amortization of 1,687 and 1,519, respectively																																																																		4,705,000
preferred stock—5,000 shares authorized as of march 31, 2007, no shares issued
common stock—no par value; 50,000 shares authorized; 27,711 and 27,647 shares issued at march 31, 2007 and december 31 2006, respectively																																																																		55,336,000
note receivable
trade receivables - less allowances of 498 and 767, respectively																																																																				23,317,000
other intangibles - less accumulated amortization of 1,824 and 1,483, respectively																																																																				4,298,000
preferred stock—5,000 shares authorized as of september 30, 2006, no shares issued
common stock—no par value; 50,000 shares authorized; 27,399 and 27,163 shares issued at september 30, 2006 and december 31 2005, respectively																																																																				51,707,000
trade receivables - less allowances of 442 and 767, respectively																																																																					23,150,000
other intangibles - less accumulated amortization of 1,634																																																																					3,595,000
and 1,483, respectively
preferred stock—5,000 shares authorized as of
june 30, 2006, no shares issued
common stock—no par value; 50,000 shares
authorized; 27,308 and 27,163 shares issued
at june 30, 2006 and december 31 2005, respectively																																																																					50,179,000
trade receivables - less allowances of 400 and 767, respectively																																																																						22,672,000
other intangibles - less accumulated amortization of 1,580 and 1,483, respectively																																																																						3,320,000
preferred stock—5,000 shares authorized as of march 31, 2006, no shares issued
common stock—no par value; 50,000 shares authorized; 27,217 and 27,163 shares issued at march 31, 2006 and december 31 2005, respectively																																																																						49,163,000
trade receivables - net																																																																							21,705,000	21,199,000		17,215,000	19,918,295
other intangibles																																																																							2,747,000	2,758,000
other liabilities																																																																							112,000	125,000	138,000
preferred stock—5,000 shares authorized as of september 30, 2005, no shares issued
common stock—no par value; 50,000 shares authorized; 27,128 and 26,486 shares issued at september 30, 2005 and december 31 2004, respectively																																																																							47,469,000
preferred stock—5,000 shares authorized as of june 30, 2005, no shares issued
common stock—no par value; 50,000 shares authorized; 26,895 and 26,486 shares issued at june 30, 2005 and december 31 2004, respectively																																																																								45,027,000
trade receivables - less allowances of 735 and 758, respectively																																																																									20,544,000
employee and other receivables																																																																									203,000	157,000	339,287
other intangibles - less accumulated amortization of 1,358 and 1,332, respectively																																																																									2,767,000
preferred stock—5,000 shares authorized as of march 31, 2005, no shares issued
common stock—no par value; 50,000 shares authorized; 26,515 and 26,486 shares issued at march 31, 2005 and december 31 2004, respectively																																																																									42,887,000
land																																																																										2,740,000	2,740,394
automobiles																																																																										88,000	87,536
patents, trademarks and licenses - net																																																																										1,942,000	2,106,451
deferred taxes payable																																																																										15,000
preferred stock—5,000 shares authorized as of june 30, 2004, no shares issued
common stock—no par value; 50,000 shares authorized; 26,429 and 26,003 shares issued at september 30, 2004 and december 31 2003, respectively																																																																										41,676,000
preferred stock—5,000,000 shares authorized as of june 30, 2004, no shares issued
common stock—no par value; 50,000,000 shares authorized; 26,334,864 and 26,002,544 shares issued at june 30, 2004 and december 31 2003, respectively																																																																											40,678,352
total liabilities and stockholders' equity

We provide you with 20 years of balance sheets for Merit Medical Systems stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Merit Medical Systems. Explore the full financial landscape of Merit Medical Systems stock with our expertly curated balance sheets.

The information provided in this report about Merit Medical Systems stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.